Anticancer agent 267
Anticancer agent 267 (Compound 5q) is the activator for RIPK3 and MLKL. Anticancer agent 267 inhibits the proliferation in a variety of cancer cell lines (IC50 for MDA-MB-231, MDA-MB-486 and MCF-7 is 9.79, 10.77 and 5.94 μM, respectively), arrests cell cycle at subG1 phase, and induces necroptosis in cell MDA-MB-231. Anticancer agent 267 exhibits antitumor activity in mouse xenograft models[1].
Product Specifications
UNSPSC
12352005
Target
Mixed Lineage Kinase; Necroptosis; RIP kinase
Related Pathways
Apoptosis; MAPK/ERK Pathway
Field of Research
Cancer
Smiles
O=C(C(N/N=C/C1=CC=C([N+]([O-])=O)S1)=O)NCC2=CC=CC=N2
Molecular Formula
C13H11N5O4S
Molecular Weight
333.32
References & Citations
[1]Akhavan R, et al., Discovery of a new hydrazone-oxamide hybrid capable of inducing necroptotic cell death in triple negative breast cancer cells. Bioorg Chem. 2025 Apr;157:108267.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400218-500 1x 500 µL
CD100 (Semaphorin-4D) (A8), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740270-500 1x 500 µL
Fibronectin (HFN7.1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880218-100 1x 100 µL
CD100 (Semaphorin-4D) (A8), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details